Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy

• Date: 2013
• Main Authors: Giesel, F.L., Flechsig P., Kuder T., Schwartz L., Wulfert S., Zechmann C., Bruchertseifer F., Haberkorn U., Kratochwil C.
• Format: Article
• Language: English
• Published: Інститут експериментальної патології, онкології і радіобіології ім. Р.Є. Кавецького НАН України 2013
• Series: Experimental Oncology
• Subjects: Original contributions
• Online Access: https://nasplib.isofts.kiev.ua/handle/123456789/145224
• Journal Title: Digital Library of Periodicals of National Academy of Sciences of Ukraine
• Cite this: Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial ¹⁷⁷Lu/⁹⁰Y-DOTATOC and ²¹³Bi-DOTATOC radiopeptide therapy / F.L. Giesel, P. Flechsig, T. Kuder, L. Schwartz, S. Wulfert, C. Zechmann, F. Bruchertseifer, U. Haberkorn, C. Kratochwil // Experimental Oncology. — 2013. — Т. 35, № 2. — С. 122-126. — Бібліогр.: 9 назв. — англ.

Aim - radiopeptide therapy with beta emitter labeled ¹⁷⁷Lu/⁹⁰Y- DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) and more recently also alpha emitting ²¹³Bi-DOTATOC are promising new treatments for neuroendocrine tumors. No early predictors for treatment response have been recognized and tumor-shrinkage a...